Lander, E. S., Linton, L. M., Birren, B., Nusbaum, C., Zody, M. C., Baldwin, J., ... & Funke, R. (2001). Erratum: Initial sequencing and analysis of the human genome: International Human Genome Sequencing Consortium (Nature (2001) 409 (860–921)). Nature, 412(6846), 565–566.

Venter, J. C., Adams, M. D., Myers, E. W., Li, P. W., Mural, R. J., Sutton, G. G., ... & Gocayne, J. D. (2001). The sequence of the human genome. science, 291(5507), 1304–1351.

Robinson A. Genomics–the future of healthcare and medicine. Prescriber. 2016;27(4):51–5.

Google Scholar 

Hansen A. Mindre av skräp-DNA i genomet. Lakartidningen. 2012;109(39):1729.

Google Scholar 

Taylor DJ, Schatz MC, Aganezov S, et al. Beyond the Human Genome Project: The age of complete human genome sequences and pangenome references. Annu Rev Genomics Hum Genet. 2024;25:77–104.

Google Scholar 

Omenn GS, Lane L, Overall CM, Lindskog C, Pineau C, Packer NH, et al. The 2024 report on the human proteome from the HUPO Human Proteome Project. J Proteome Res. 2024;23(12):5296–311.

Google Scholar 

Eisenstein M. The rise of long-read sequencing. Nature. 2020;577(7792):16–7.

Google Scholar 

Nassif, H., Albrecht, M., & Hofestädt, R. (2023). Computational biology today: Integration of mathematics, physics, and computer science in modern genomics. Briefings in Bioinformatics, 24(5).

Sayers EW, Cavanaugh M, Clark K, Pruitt KD, Sherry ST, Yankie L, Karsch-Mizrachi I. GenBank 2023 update. Nucleic acids research. 51(D1):D141–4.

Google Scholar 

Cock, P. J. A., Antao, T., Chang, J. T., Chapman, B. A., Cox, C. J., Dalke, A., & others. (2023). Biopython: Freely available Python tools for computational molecular biology and bioinformatics—2023 update. Bioinformatics, 39(4), btad123.

Gruber M, Brand A. Ethical considerations for large-scale genomic data sharing in precision medicine. Nat Rev Genet. 2024;25(2):95–108.

Google Scholar 

Ingelman-Sundberg M. Pharmacogenetics: an opportunity for a safer and more efficient pharmacotherapy. J Intern Med. 2001;250(3):186–200.

Google Scholar 

International Cancer Genome Consortium (ICGC) & The Cancer Genome Atlas (TCGA) Pan-Cancer Analysis Working Group. Pan-cancer analysis of whole genomes. Nature. 2020;578(7793):82–93.

Google Scholar 

Chu ATW, Chung BHY. Personalised genomic medicine is shaping the future of healthcare. J Transl Genet Genomics. 2024;8(1):49–54.

Google Scholar 

Grosu, O. (2022). Predictive, preventive, personalized and participatory medicine (4P): Narrative review. Bulletin of the Academy of Sciences of Moldova. Medical Sciences, 2022(3).

Vitorino R. Transforming clinical research: the power of high-throughput omics integration. Proteomes. 2024;12(3):25.

Google Scholar 

Wagle N, Berger MF, Davis MJ, Blumenstiel B, DeFelice M, Pochanard P, et al. High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. Cancer Discov. 2012;2(1):82–93.

Google Scholar 

Cecchi F, Rabe DC, Bottaro DP. Targeting the HGF/Met signaling pathway in cancer therapy. Expert Opin Ther Targets. 2012;16(6):553–72.

Google Scholar 

Mattick JS, Dziadek MA, Terrill BN, Kaplan W, Spigelman AD, Bowling FG, et al. The impact of genomics on the future of medicine and health. Med J Aust. 2014;201(1):17–20.

Google Scholar 

Welch JS, Westervelt P, Ding L, Larson DE, Klco JM, Kulkarni S, et al. Use of whole-genome sequencing to diagnose a cryptic fusion oncogene. JAMA. 2011;305(15):1577–84.

Google Scholar 

Lo YM, Chiu RW. Plasma nucleic acid analysis by massively parallel sequencing: pathological insights and diagnostic implications. J Pathol. 2011;225(3):318–23.

Google Scholar 

Sheffield LJ, Phillimore HE. Clinical use of pharmacogenomic tests in 2009. Clin Biochem Rev. 2009;30(2):55.

Google Scholar 

Harper AR, Topol EJ. Pharmacogenomics in clinical practice and drug development. Nat Biotechnol. 2012;30(11):1117–24.

Google Scholar 

Collins FS. Mining for therapeutic gold. Nat Rev Drug Discovery. 2011;10(6):397–397.

Google Scholar 

Mardis ER, Wilson RK. Tracing the path of sequencing through the age of genomic medicine. Nat Rev Genet. 2025;26:719–34.

Google Scholar 

International Human Genome Sequencing Consortium. Initial sequencing and analysis of the human genome. Nature. 2001;409:860–921.

Google Scholar 

Human Pangenome Reference Consortium. A human pangenome reference captures genetic diversity and improves variant interpretation. Nature. 2023;617:312–24.

Google Scholar 

Gibbs RA, et al. Celebrating 20 years of human genomics: a journey of discovery. Hum Genomics. 2024;18:1.

Google Scholar 

Metzker ML. Sequencing technologies—the next generation. Nat Rev Genet. 2010;11:31–46.

Google Scholar 

Ashley EA. Towards precision medicine. Nat Rev Genet. 2016;17:507–22.

Google Scholar 

National Research Council. Toward precision medicine: building a knowledge network for biomedical research and a new taxonomy of disease. Washington, DC: National Academies Press; 2011.

Google Scholar 

Wigby KM, Vissers LELM, Biesecker LG, et al. First-line genome sequencing for rare disorders. NPJ Genom Med. 2024;9:15.

Google Scholar 

Currie, G., Delles, C. Precision medicine and personalized medicine in cardiovascular disease. In Sex-Specific Analysis of Cardiovascular Function. Springer, Cham; 2018. p. 589–605

Levy, B. (2020). Building Comprehensive Enterprise-Scale PPM Clinical Informatics Capability and Capacity. In Personalized and Precision Medicine Informatics (pp. 305–317). Springer, Cham.

Vogenberg FR, Barash CI, Pursel M. Personalized medicine: part 1: evolution and development into theranostics. Pharm Ther. 2010;35(10):560.

Google Scholar 

Alhajji L, Nemeroff CB. Personalized medicine and mood disorders. Psychiatr Clin. 2015;38(3):395–403.

Google Scholar 

Dickmann LJ, Ware JA. Pharmacogenomics in the age of personalized medicine. Drug Discov Today Technol. 2016;21:11–6.

Google Scholar 

Mathur S, Sutton J. Personalized medicine could transform healthcare. Biomed Rep. 2017;7(1):3–5.

Google Scholar 

Khan A, Barapatre AR, Babar N, Doshi J, Ghaly M, Patel KG, et al. Genomic medicine and personalized treatment: a narrative review. Annals of medicine and surgery (2012). 2025;87(3):1406–14. https://doi.org/10.1097/MS9.0000000000002965.

Article  Google Scholar 

Jamalinia M, Weiskirchen R. Advances in personalized medicine: translating genomic insights into targeted therapies for cancer treatment. Ann Transl Med. 2025;13(2):18.

Google Scholar 

Khan SA, Khan S, Kausar H, Sharma P, Adhikari A, Parajuli SB, et al. Pharmacogenomics and risk stratification in cardiovascular care: insights from randomized controlled trials. Medicine (Baltimore). 2025;104(24):e42868.

Google Scholar 

Méndez-Vidal C, Bravo-Gil N, Pérez-Florido J, Marcos-Luque I, Fernández RM, Fernández-Rueda JL, González-del Pozo M, Martín-Sánchez M, Fernández-Suárez E, Mena M, Carmona R. A genomic strategy for precision medicine in rare diseases: integrating customized algorithms into clinical practice. Journal of translational medicine. 2025;23(1):86.

Google Scholar 

Hays, P. Personalized medicine beyond cancer: Impact on other diseases. Open Access Government, October, 118–119. 2024.

Patel HN, Patel NH, Mathukiya S, Parekh BR, Purohit KA, Patel SP, et al. Genomic medicine: applications in disease prevention and treatment. J Pharm Bioallied Sci. 2025;17(Suppl. 2):S1101–3.

Google Scholar 

Ghoreyshi N, Heidari R, Farhadi A, Chamanara M, Farahani N, Vahidi M, et al. Next-generation sequencing in cancer diagnosis and treatment: clinical applications and future directions. Discov Oncol. 2025;16(1):578.

Google Scholar 

Serratì, S., De Summa, S., Pilato, B., Petriella, D., Lacalamita, R., Tommasi, S. and Pinto, R., 2016. Next-generation sequencing: advances and applications in cancer diagnosis. OncoTargets and therapy, pp.7355–7365.

Rajesh, P., Kaur, H. and Rajesh, C., 2025. Introduction to Cancer Genetic Testing. In Clinical Applications of Cancer Genetic Testing (pp. 1–22). CRC Press.

Sylva RM, Ahmed SI. Targeted therapies in cancer. Surg Infect (Larchmt). 2024;42(3):150–5.

Google Scholar 

Manca P, Corti F, Intini R, Mazzoli G, Miceli R, Germani MM, et al. Tumour mutational burden as a biomarker in patients with mismatch repair deficient/microsatellite instability-high metastatic colorectal cancer treated with immune checkpoint inhibitors. Eur J Cancer. 2023;187:15–24.

Google Scholar 

Klempner SJ, Fabrizio D, Bane S, Reinhart M, Peoples T, Ali SM, et al. Tumor mutational burden as a predictive biomarker for response to immune checkpoint inhibitors: a review of current evidence. Oncologist. 2020;25(1):e147–59.

Google Scholar 

Allen TA. The role of circulating tumor cells as a liquid biopsy for cancer: advances, biology, technical challenges, and clinical relevance. Cancers. 2024;16(7):1377.

Google Scholar 

Geifman, N. and Butte, A.J., 2016. Do cancer clinical trial populations truly represent cancer patients? A comparison of open clinical trials to the cancer genome atlas. In Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing (Vol. 21, p. 309).

Korniyenko, T., 2023. Genetic screening and prognostic markers of the risk of development in patients with dilated cardiomyopathy based on the analysis of the results of modern studies. Revista Latinoamericana de Hipertension, 18(6).

Meer, M., Meer, M., Mumtaz, M. and Jawed, U., 2025. Role of Genetics in Early-Onset Cardiovascular Disease. Cureus, 17(6).

Ingelman-Sundberg M, Pirmohamed M. Precision medicine in cardiovascular therapeutics: evaluating the role of pharmacogenetic analysis prior to drug treatment. J Intern Med. 2024;295(5):583–98.

Google Scholar 

Hirota T, Fujita Y, Ieiri I. An updated review of pharmacokinetic drug interactions and pharmacogenetics of statins. Expert Opin Drug Metab Toxicol. 2020;16(9):809–22.

Google Scholar 

Gupta A, Shah K, Shukla A. Bridging traditional risk factors and genetic insights: a review on polygenic risk scores in cardiovascular diseases. Adv Biomark Sci Technol. 2025. https://doi.org/10.1016/j.abst.2025.09.002.

Article  Google Scholar 

O’Sullivan JW, Raghavan S, Marquez-Luna C, Luzum JA, Damrauer SM, Ashley EA, et al. Polygenic risk scores for cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2022;146(8):e93–118.

Google Scholar 

Myrou A, Barmpagiannos K, Ioakimidou A, Savopoulos C. Molecular biomarkers in neurological diseases: advances in diagnosis and prognosis. Int J Mol Sci. 2025;26(5):2231.

Google Scholar 

Kitaoka Y, Uchihashi T, Kawata S, Nishiura A, Yamamoto T, Hiraoka SI, et al. Role and potential of artificial intelligence in biomarker discovery and development of treatment strategies for amyotrophic lateral sclerosis. Int J Mol Sci. 2025;26(9):4346.

Google Scholar 

Firdaus Z, Li X. Unraveling the genetic landscape of neurological disorders: insights into pathogenesis, techniques for variant identification, and therapeutic approaches. Int J Mol Sci. 2024;25(4):2320.

Google Scholar 

De Deyn L, Sleegers K. The impact of rare genetic variants on Alzheimer disease. Nat Rev Neurol. 2025;21(3):127–39.

Google Scholar 

Kshirsagar, N., Pai, S. and Chaudhari-Gunjal, V., 2025. Genetics, genomics, and drug prescribing. In Genomics, Populations, and Society (pp. 165–182). Academic Press.

TumkurSattar, A.H., Abushoumi, F., Al Dobayan, Z. and Al-Ghamdi, F., 2023. Investigate how genetic variations impact drug response and explore the integration of pharmacogenomics into clinical practice. European Journal of Cardiovascular Medicine, 13(4).

Hafeez S, Maryam S. Pharmacogenomics-based nanoprecision medicine. In: Nanotheranostics and Precision Oncology. Academic Press; 2026. p. 505–33.

Google Scholar 

Hamburg MA, Collins FS. The path to personalized medicine. N Engl J Med. 2010;363(4):301–4.

Google Scholar 

Byers P. The role of genomics in medicine-past, present and future. J Zhejiang Univ Sci B. 2006;7(2):159.

Google Scholar 

Khurjekar K, Ausekar A, Jotshi J. Genomics in spine health. J Trauma. 2018;13(1):4–7.

Google Scholar 

Altmann A, Beerenwinkel N, Sing T, Savenkov I, Däumer M, Kaiser R, et al. Improved prediction of response to antiretroviral combination therapy using the genetic barrier to drug resistance. Antivir Ther. 2007;12(2):169.

Google Scholar 

Zhang H, Klareskog L, Matussek A, Pfister SM, Benson M. Translating genomic medicine to the clinic: challenges and opportunities. Genome Med. 2019;11(1):9.

Google Scholar 

Dong L, Wang W, Li A, Kansal R, Chen Y, Chen H, et al. Clinical next generation sequencing for precision medicine in cancer. Curr Genomics. 2015;16(4):253–63.

Google Scholar 

Teutsch, S. M., Bradley, L. A., Palomaki, G. E., Haddow, J. E., Piper, M., Calonge, N., ... & Berg, A. O. (2009). The evaluation of genomic applications in practice and prevention (EGAPP) initiative: methods of the EGAPP working group. Genetics in medicine, 11(1), 3–14.

McKinnon RA, Ward MB, Sorich MJ. A critical analysis of barriers to the clinical implementation of pharmacogenomics. Ther Clin Risk Manag. 2007;3(5):751.